{"id":"W4387160441","doi":"10.1016/s2666-5247(23)00177-5","title":"Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland","year":2023,"lang":"en","type":"article","venue":"The Lancet Microbe","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"Medical Research Council; Shionogi; University of Oxford; Department of Health and Social Care; Moderna; Coalition for Epidemic Preparedness Innovations; Seqirus; AstraZeneca; National Institute for Health and Care Research; Bill and Melinda Gates Foundation","keywords":"Immunogenicity; Medicine; Randomized controlled trial; Cohort; Internal medicine; Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Antibody; Immunology; Disease; Infectious disease (medical specialty)","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002039502,0.0006127613,0.001256904,0.0002267976,0.0001896315,0.0004416047,0.000412407,0.0007288852,0.001360621],"category_scores_gemma":[0.001645083,0.0004592442,0.0007804664,0.0002405912,0.0008547239,0.0005037527,0.0003127682,0.0009690925,0.0002703974],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007196101,"about_ca_system_score_gemma":0.0009276156,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008618162,"about_ca_topic_score_gemma":0.001150818,"domain_scores_codex":[0.9987941,0.0006358982,0.0001043259,0.0001721709,0.0001509599,0.0001425414],"domain_scores_gemma":[0.9990553,0.0001690827,0.0003631598,0.0000887467,0.00006955638,0.0002541255],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8437743,0.02596914,0.0174589,0.001123325,0.001121467,0.0001361444,0.0004066374,0.0008670499,0.05512131,0.0001226631,0.0005605863,0.05333857],"study_design_scores_gemma":[0.1749628,0.7630662,0.05210632,0.00004565253,0.001003676,0.000184025,0.0001167431,0.0005298395,0.006561166,0.00006480394,0.001333425,0.00002533568],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9984255,0.000589378,0.0001337681,0.00003310883,0.00001743908,0.000497897,0.00008386842,0.000005366056,0.0002136203],"genre_scores_gemma":[0.9982539,0.0003671405,0.0003562862,0.00009891919,0.00002866869,0.0004228576,0.0001174126,0.000003534964,0.0003511843],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002039502,"threshold_uncertainty_score":0.01078606,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05338598424773385,"score_gpt":0.3800198132191175,"score_spread":0.3266338289713837,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}